PDE5 inhibitor medications

Recent studies show around 50% of people stop using PDE5 inhibitor medications1
1. Carvalheira et al., “Dropout in the Treatment of erectile dysfunction (ED) with PDE5: A Study on Predictors and a Qualitative Analysis of Reasons for Discontinuation,” Journal of Sexual Medicine, May 2012
LTR Pharma expects expedited regulatory approval for SPONTAN (vardenafil HCL nasal spray) by repurposing an already regulatory cleared PDE5 inhibitor - intranasal delivery of vardenafil, a proven and effective oral treatment for ED.
Benefits of SPONTAN® (vardenafil HCL nasal spray)
- Non-invasive
- Bypasses the Liver and first pass metabolism
- Large highly vascular surface of the inner nostrils improves bioavailability
- Provides therapeutic effect at lower dose
- Provides faster onset of action
- Reduces the risk of systemic exposure and side effects
- More convenient for certain patient groups such as those with dysphagia